A trio of Shire veterans launched OncoOne on Wednesday with a €13 million series A round and a batch of biologics against oxidized MIF, a highly selective tumor antigen that was abandoned by the pharma...

CFO Siddharth Mittal will succeed Arun Chandavarkar as CEO and joint managing director of Biocon Ltd. (NSE:BIOCON; BSE:532523). Chandavarkar, who retired last month, had been with the Indian biopharma since 1990. Mittal joined in 2013...

The Business Roundtable, a club of CEOs of many of the largest U.S. corporations, has given biopharma companies a new impetus for telling the public how they plan to live up to their social commitments....

Since 2001, gene therapy company Asklepios has subsisted chiefly on cash from licensing deals or transaction fees on programs sold off to biopharmas. Now, with $225 million in new series A funding from TPG Capital...

As Johnson & Johnson gears up to launch its Shanghai JLABS site early next year, the incubator’s head, Sharon Chan, has pegged lung cancer as one of the first priorities. Chan sees opportunity in China...

HHS partnered with Opiant Pharmaceuticals Inc. (NASDAQ:OPNT) to accelerate development of the company's OPNT003, an intranasal formulation of opioid receptor antagonist nalmefene. Under a one-year contract with HHS's Biomedical Advanced Research and Development Authority, Opiant...

HHS partnered with Opiant Pharmaceuticals Inc. (NASDAQ:OPNT) to accelerate development of the company's OPNT003, an intranasal formulation of opioid receptor antagonist nalmefene. Under a one-year contract with HHS's Biomedical Advanced Research and Development Authority, Opiant...

Halozyme Therapeutics Inc. is quickly expanding the reach of its Enhanze platform on the back of regulatory approvals for products that are now gaining market share, plus a playbook for streamlined early development it can...

The Hong Kong stock exchange is well aware its investor base is new to the high-risk, high-reward nature of its newly hatched biotech chapter and has no qualms about admitting its own lack of expertise....

Shire plc (LSE:SHP; NASDAQ:SHPG) granted Caladrius Biosciences Inc. (NASDAQ:CLBS) an exclusive, worldwide license to data and regulatory filings for a late-stage CD34+ cell therapy program to treat refractory angina. Shire will receive an upfront payment...